Renal toxicities in the peri-HSCT period

Malika Kapadia, Terry Wikle Shapiro, Robert Greiner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Renal dysfunction within the first 100 days post-hematopoietic stem cell transplantation (HSCT) is common. Many HSCT patients have some degree of renal dysfunction prior to HSCT, and the degree of this dysfunction impacts the extent of renal dysfunction that can occur during the preengraftment and early post-engraftment periods of the HSCT course. Renal dysfunction may be due to renal tubule damage, compromised renal blood flow, and obstruction or irritation of post-renal structures. Renal dysfunction impairs the ability of the kidneys to maintain acid-base and electrolyte balance as well as maintain fluid balance and eliminate waste. The renal complications post-HSCT are discussed in Chap. 22. The most common renal toxicities are related to medications frequently used during the peri-HSCT period. These include calcineurin inhibitors, antifungal agents, antibiotics (particularly aminoglycosides), and antiviral agents. In addition, components of conditioning regimens such as alkylators and irradiation to the bladder can cause significant renal toxicity. An infrequent but very serious renal complication is hemorrhagic cystitis which is the focus of this chapter. The remainder of HSCT-associated renal complications is addressed in Chap. 22.

Original languageEnglish (US)
Title of host publicationHematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist
PublisherSpringer International Publishing
Pages235-240
Number of pages6
ISBN (Electronic)9783319631462
ISBN (Print)9783319631448
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hematopoietic Stem Cell Transplantation
Kidney
Water-Electrolyte Balance
Antifungal Agents
Cystitis
Acid-Base Equilibrium
Renal Circulation
Alkylating Agents
Aminoglycosides
Antiviral Agents
Urinary Bladder

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kapadia, M., Shapiro, T. W., & Greiner, R. (2017). Renal toxicities in the peri-HSCT period. In Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist (pp. 235-240). Springer International Publishing. https://doi.org/10.1007/978-3-319-63146-2_16
Kapadia, Malika ; Shapiro, Terry Wikle ; Greiner, Robert. / Renal toxicities in the peri-HSCT period. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, 2017. pp. 235-240
@inbook{240f3fa9ea7d4da198fc7461b3ffb876,
title = "Renal toxicities in the peri-HSCT period",
abstract = "Renal dysfunction within the first 100 days post-hematopoietic stem cell transplantation (HSCT) is common. Many HSCT patients have some degree of renal dysfunction prior to HSCT, and the degree of this dysfunction impacts the extent of renal dysfunction that can occur during the preengraftment and early post-engraftment periods of the HSCT course. Renal dysfunction may be due to renal tubule damage, compromised renal blood flow, and obstruction or irritation of post-renal structures. Renal dysfunction impairs the ability of the kidneys to maintain acid-base and electrolyte balance as well as maintain fluid balance and eliminate waste. The renal complications post-HSCT are discussed in Chap. 22. The most common renal toxicities are related to medications frequently used during the peri-HSCT period. These include calcineurin inhibitors, antifungal agents, antibiotics (particularly aminoglycosides), and antiviral agents. In addition, components of conditioning regimens such as alkylators and irradiation to the bladder can cause significant renal toxicity. An infrequent but very serious renal complication is hemorrhagic cystitis which is the focus of this chapter. The remainder of HSCT-associated renal complications is addressed in Chap. 22.",
author = "Malika Kapadia and Shapiro, {Terry Wikle} and Robert Greiner",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-63146-2_16",
language = "English (US)",
isbn = "9783319631448",
pages = "235--240",
booktitle = "Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist",
publisher = "Springer International Publishing",

}

Kapadia, M, Shapiro, TW & Greiner, R 2017, Renal toxicities in the peri-HSCT period. in Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, pp. 235-240. https://doi.org/10.1007/978-3-319-63146-2_16

Renal toxicities in the peri-HSCT period. / Kapadia, Malika; Shapiro, Terry Wikle; Greiner, Robert.

Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, 2017. p. 235-240.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Renal toxicities in the peri-HSCT period

AU - Kapadia, Malika

AU - Shapiro, Terry Wikle

AU - Greiner, Robert

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Renal dysfunction within the first 100 days post-hematopoietic stem cell transplantation (HSCT) is common. Many HSCT patients have some degree of renal dysfunction prior to HSCT, and the degree of this dysfunction impacts the extent of renal dysfunction that can occur during the preengraftment and early post-engraftment periods of the HSCT course. Renal dysfunction may be due to renal tubule damage, compromised renal blood flow, and obstruction or irritation of post-renal structures. Renal dysfunction impairs the ability of the kidneys to maintain acid-base and electrolyte balance as well as maintain fluid balance and eliminate waste. The renal complications post-HSCT are discussed in Chap. 22. The most common renal toxicities are related to medications frequently used during the peri-HSCT period. These include calcineurin inhibitors, antifungal agents, antibiotics (particularly aminoglycosides), and antiviral agents. In addition, components of conditioning regimens such as alkylators and irradiation to the bladder can cause significant renal toxicity. An infrequent but very serious renal complication is hemorrhagic cystitis which is the focus of this chapter. The remainder of HSCT-associated renal complications is addressed in Chap. 22.

AB - Renal dysfunction within the first 100 days post-hematopoietic stem cell transplantation (HSCT) is common. Many HSCT patients have some degree of renal dysfunction prior to HSCT, and the degree of this dysfunction impacts the extent of renal dysfunction that can occur during the preengraftment and early post-engraftment periods of the HSCT course. Renal dysfunction may be due to renal tubule damage, compromised renal blood flow, and obstruction or irritation of post-renal structures. Renal dysfunction impairs the ability of the kidneys to maintain acid-base and electrolyte balance as well as maintain fluid balance and eliminate waste. The renal complications post-HSCT are discussed in Chap. 22. The most common renal toxicities are related to medications frequently used during the peri-HSCT period. These include calcineurin inhibitors, antifungal agents, antibiotics (particularly aminoglycosides), and antiviral agents. In addition, components of conditioning regimens such as alkylators and irradiation to the bladder can cause significant renal toxicity. An infrequent but very serious renal complication is hemorrhagic cystitis which is the focus of this chapter. The remainder of HSCT-associated renal complications is addressed in Chap. 22.

UR - http://www.scopus.com/inward/record.url?scp=85043315302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043315302&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-63146-2_16

DO - 10.1007/978-3-319-63146-2_16

M3 - Chapter

SN - 9783319631448

SP - 235

EP - 240

BT - Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

PB - Springer International Publishing

ER -

Kapadia M, Shapiro TW, Greiner R. Renal toxicities in the peri-HSCT period. In Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing. 2017. p. 235-240 https://doi.org/10.1007/978-3-319-63146-2_16